SCHEMBL1850790

SCHEMBL1850790

CC(OC(=O)CCl)c1ccc2oc(C(N)=O)c(NC(=O)CCl)c2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TEAD1 P28347 1/20 0.57
YAP1 P46937 1/20 0.57
TEAD4 Q15561 1/20 0.57
TEAD2 Q15562 1/20 0.57
KDM4E B2RXH2 5/20 0.47
NPSR1 Q6W5P4 2/20 0.44
KMT2A Q03164 5/20 0.43
MAPT P10636 3/20 0.43
ATM Q13315 1/20 0.43
MAPK10 P53779 3/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 3/20 0.40
POLB P06746 1/20 0.40
PKM P14618 1/20 0.40
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
ALOX15 P16050 1/20 0.39
MEN1 O00255 3/20 0.37
TSHR P16473 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1852546 0.77 KDM4E (0.72) TEAD1YAP1TEAD4TEAD2KDM4E
SCHEMBL1858218 0.76 TEAD1 (0.68) TEAD1YAP1TEAD4TEAD2KDM4E
SCHEMBL1853830 0.76 TEAD1 (0.68) TEAD1YAP1TEAD4TEAD2KDM4E
SCHEMBL4277185 0.76 TEAD1 (0.58) TEAD1YAP1TEAD4TEAD2KDM4E
SCHEMBL24845910 0.73 TEAD1 (1.00) TEAD1YAP1TEAD4TEAD2KDM4E
SCHEMBL1852523 0.73 TEAD1 (0.62) TEAD1YAP1TEAD4TEAD2KDM4E
SCHEMBL13699835 0.69 KDM4E (0.70) TEAD1YAP1TEAD4TEAD2KDM4E
SCHEMBL12559906 0.68 FAAH (0.41) KDM4EMAPTALDH1A1LMNATP53
SCHEMBL1856974 0.68 KMT2A (0.59) TEAD1YAP1TEAD4TEAD2KDM4E
SCHEMBL13699834 0.67 KDM4E (0.51) TEAD1YAP1TEAD4TEAD2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097419-B1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS INC (US) 2011-05-25 EP disclosed
US-20090247559-A1 Benzofuropyrimidinones EXELIXIS, INC. (US) 2009-10-01 US disclosed
US-20090247559-A1 Benzofuropyrimidinones EXELIXIS, INC. (US) 2009-10-01 US disclosed
EP-2097419-A1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS Exelixis, Inc. (US) 2009-09-09 EP disclosed
WO-2009086264-A1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS, INC. (US) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247559-A1 Benzofuropyrimidinones F12, BRI3BP, BRD1 TEAD1 612/4885YAP1 2062/4885TEAD4 598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.